Clinical Trials Browser

Phase 1/2 × Triple Negative Breast Neoplasms × surufatinib × Clear all

NCT05746728 2023-04-06

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Phase 1/2 Unknown

Triple Negative Breast Neoplasms